Recent Stories 2006-03-16 See all News 08:32:01 - Donnerstag
Imagin Molecular Corporation Targets Self-Insured Corporate Healthcare Companies
Business Editors
OAK BROOK, Ill.--(BUSINESS WIRE)--March 16, 2006-- Imagin Molecular Corporation (OTCBB:IMGM) (Imagin) announced today identification of additional markets to benefit from their Coronary Disease Reversal and Prevention Centers. Imagin it set to release a landmark report that will demonstrate a 25% or greater reduction of total coronary disease management costs. The report will further show direct and indirect financial benefits for corporations who choose to self-insure. Imagin intends to offer full outsourced solutions to large self insurers such as unions, federal and local government agencies and large corporations such as General Motors, Wal-Mart, etc. Imagin through its affiliates has access to a clinical and economic database of Coronary Artery Disease (CAD) patients and their complementing applications, results and outcomes. Imagin will use this information to assist in their new implementation for patients and corporations to better detect and treat coronary disease, lower health management and treatment costs, lower obesity and diabetic rates, lower mortality rates and increase productivity in the work place through a healthier more stable work force. Imagin's solution and approach represents the inevitable shift from traditional methods of coronary disease management to less invasive imaging followed by non-surgical therapies. Imagin, through its Coronary Disease Reversal and Prevention Centers, is positioned to be the first company to offer such techniques to larger companies as a solution to their largest expenditure of healthcare dollars. Joseph Oliverio, CEO of Imagin states, "Imagin's access to data and execution model will position Imagin to be the logical choice of coronary disease management contracts from self-insured large corporations. Imagin will be the first to demonstrate benefits with real patient data that will prove substantial patient and economic improvements much greater than the current practice. In the past, studies have only demonstrated theory through econometric data without the clinical applications and results that Imagin possess. With cooperation from Positron Corporation, we will be able to deliver affordable PET and PET / CT devices for widespread distribution to Imagin supported centers markets. In addition Positron Corporation is currently implementing innovative software solutions specific to the coronary disease reversal and prevention market further positioning them to be the market leader in the industry."
About Imagin Molecular Corporation:
Imagin Molecular Corporation strategy and focus is dedicated to business opportunities in positron emission tomography (PET) manufacturing and the diagnosis of cancer, heart disease and neurological diseases. PET is an advanced medical diagnostic imaging procedure used by physicians in the detection of certain cancers, coronary disease and neurological disorders including Alzheimer's disease. Imagin Molecular Corporation has positioned the Company to be a factor in PET and ancillary molecular imaging businesses. Imagin Nuclear Partners, a wholly owned subsidiary of Imagin Molecular Corporation, is a full-service joint venture molecular imaging partner that will own, operate and administer out-patient medical diagnostic imaging centers that utilizes PET and PET/CT scanning equipment. Imagin Nuclear Partners specializes in using evidence based bioinformatics specifically positioned in the market to provide the maximal cost effective benefit to their joint venture partner and the community. Imagin Molecular Corporation is also the parent of Cipher Multimedia, Inc., a new media marketing and distribution solution company that provides a Distribution Solution for publishers of digital content.
About Positron:
Positron Corporation designs, manufactures, markets and supports advanced medical imaging devices utilizing positron emission tomography (PET) technology under the trade name POSICAM(TM) systems. POSICAM(TM) systems incorporate patented and proprietary technology for the diagnosis and treatment of patients in the areas of oncology, cardiology and neurology. POSICAM(TM) systems are in use at leading medical facilities, including the University of Texas -- Houston Health Science Center; Buffalo Cardiology and Pulmonary Associates in Buffalo, New York; Beth Israel Medical Center in New York City, NY; The Hear Center of Niagara in Niagara Falls, NY; Emory Crawford Long Hospital Carlyle Fraser Heart Center in Atlanta; and Nishidai Clinic (Diagnostic Imaging Center) in Tokyo. Additional information may be found at http://www.positron.com/.
Forward Looking Statements
Certain statements in this release, and other written or oral statements made by the Company, including the use of the words "expect," "anticipate," "estimate," "project," "forecast," "outlook," "target," "objective," "plan," "goal," "pursue," "on track," and similar expressions, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied. The Company assumes no obligation and does not intend to update these forward looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward looking statements include, without limitation: competitive and general economic conditions, adverse effects of litigation, the timely development and acceptance of services, significant changes in the competitive environment, the failure to generate or the loss of significant numbers of customers, the loss of senior management, increased government regulation or the company's failure to integrate its acquired companies to achieve the synergies and efficiencies described in the "Management's Discussion and Analysis" section of the Company's Form 10-KSB and other reports and filings with the Securities and Exchange Commission, which may be revised or supplemented in subsequent reports on SEC Forms 10-QSB and 8-K. For further information please contact Joseph Oliverio at Imagin Molecular Corporation at (716) 989-4411.
KEYWORD: NORTH AMERICA ILLINOIS NEW YORK UNITED STATES INDUSTRY KEYWORD: HEALTH CARDIOLOGY HOSPITALS MEDICAL DEVICES RADIOLOGY RESEARCH & SCIENCE PROFESSIONAL SERVICES HUMAN RESOURCES INSURANCE SOURCE: Imagin Molecular Corporation
CONTACT INFORMATION: Imagin Molecular Corporation Joseph Oliverio, 716-989-4411 |